4//SEC Filing
Stalfort John A III 4
Accession 0001209191-21-046030
CIK 0001576885other
Filed
Jul 7, 8:00 PM ET
Accepted
Jul 8, 6:17 PM ET
Size
12.9 KB
Accession
0001209191-21-046030
Insider Transaction Report
Form 4
Stalfort John A III
Director
Transactions
- Conversion
Series A-1 Preferred
2021-07-06−130,180→ 0 total→ Common Stock (130,180 underlying) - Conversion
Common Stock
2021-07-06+130,180→ 137,324 total - Conversion
Common Stock
2021-07-06+131,595→ 131,595 total(indirect: See footnote) - Conversion
Series B Preferred
2021-07-06−131,595→ 0 total(indirect: See footnote)→ Common Stock (131,595 underlying) - Purchase
Common Stock
2021-07-06$16.00/sh+35,000$560,000→ 172,324 total
Footnotes (2)
- [F1]On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and each share of Series B Convertible Preferred Stock converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
- [F2]The securities are held by Gineane Holly Stalfort, as Trustee of the John A. Stalfort III 2018 Irrevocable Trust under agreement dated as of October 25, 2018.
Documents
Issuer
Acumen Pharmaceuticals, Inc.
CIK 0001576885
Entity typeother
Related Parties
1- filerCIK 0001709418
Filing Metadata
- Form type
- 4
- Filed
- Jul 7, 8:00 PM ET
- Accepted
- Jul 8, 6:17 PM ET
- Size
- 12.9 KB